RTW BIOTECH OPPORTUNITIES LTD - Annual Results for the year ended 31 December 2025

RTW Biotech Opportunities Ltd reported strong FY2025 financial results, with NAV per share rising 36% and continued outperformance versus biotech indices, underscoring consistent company performance and alpha generation since IPO. Growth was driven by public portfolio gains, including M&A and IPO activity, while the private portfolio remained stable with new investments supporting the long-term growth strategy. The firm’s full life cycle investment approach—spanning early-stage innovation to commercialisation—continues to enhance returns, with a diversified portfolio positioned for revenue growth and improving margins. The biotech sector showed early signs of recovery following a prolonged downturn, supported by increasing deal activity, a reopening IPO market, and structural tailwinds such as patent expiries and rising pharma demand for innovation. With a strong balance of public and private assets and a pipeline nearing monetisation, RTW remains well positioned to capitalise on sector recovery, deliver sustained earnings growth, and drive long-term shareholder value.